The present invention provides pyrazole derivatives represented by the general formula: ##STR00001## wherein R.sup.1 represents H, an optionally substituted C.sub.1-6 alkyl group etc.; one of Q and T represents a group selected from the following groups: ##STR00002## , and the other represents --(CH.sub.2).sub.n--Ar wherein Ar represents an optionally substituted C.sub.6-10 aryl group or an optionally substituted C.sub.1-9 heteroaryl group; and n represents an integral number from 0 to 2, an optionally substituted C.sub.1-6 alkoxyl group, an optionally substituted amino group, an optionally substituted C.sub.2-9 heterocycloalkyl group or an optionally substituted heterocycle-fused phenyl group; R represents an optionally substituted C.sub.3-8 cycloalkyl group, an optionally substituted C.sub.6-10 aryl group etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human 1,5-anhydroglucitol/fructose/mannose transporter and are useful as agents for the prevention, inhibition of progression or treatment of a disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose or a disease associated with hyperglycemia (e.g., diabetic complications, diabetes, etc.), and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.